SCHEMBL1491378

SCHEMBL1491378

O=C(CCCCCCC(=O)Nc1cccc(C(=O)N[C@H](C(=O)O)c2ccccc2)c1)NO

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 15/20 0.58
HDAC1 Q13547 14/20 0.58
HDAC8 Q9BY41 14/20 0.57
HDAC11 Q96DB2 13/20 0.57
HDAC3 O15379 12/20 0.57
HDAC2 Q92769 12/20 0.57
HDAC10 Q969S8 12/20 0.57
HDAC4 P56524 11/20 0.57
HDAC7 Q8WUI4 11/20 0.57
HDAC9 Q9UKV0 11/20 0.57
HDAC5 Q9UQL6 11/20 0.57
EGFR P00533 3/20 0.57
NCOR2 Q9Y618 3/20 0.56
KDM4E B2RXH2 1/20 0.56
BRD4 O60885 1/20 0.56
NCOR1 O75376 1/20 0.56
NR1I2 O75469 1/20 0.56
CYP3A4 P08684 1/20 0.56
LTA4H P09960 1/20 0.56
NR0B1 P51843 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1491381 1.00 HDAC6 (0.58) HDAC6HDAC1HDAC8HDAC11HDAC3
SCHEMBL12673053 0.89 HDAC6 (0.54) HDAC6HDAC1HDAC8HDAC11HDAC3
SCHEMBL1491509 0.87 HDAC6 (0.60) HDAC6HDAC1HDAC8HDAC11HDAC3
SCHEMBL1491503 0.87 HDAC6 (0.60) HDAC6HDAC1HDAC8HDAC11HDAC3
SCHEMBL1491338 0.84 HDAC6 (0.48) HDAC6HDAC1HDAC8HDAC11HDAC3
SCHEMBL1491343 0.84 HDAC6 (0.48) HDAC6HDAC1HDAC8HDAC11HDAC3
SCHEMBL1491606 0.81 HDAC1 (0.54) HDAC6HDAC1HDAC8HDAC11HDAC3
SCHEMBL1491608 0.81 HDAC1 (0.54) HDAC6HDAC1HDAC8HDAC11HDAC3
SCHEMBL1491597 0.81 HDAC1 (0.54) HDAC6HDAC1HDAC8HDAC11HDAC3
SCHEMBL1491600 0.81 HDAC1 (0.54) HDAC6HDAC1HDAC8HDAC11HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9133104-B2 Enzyme inhibitors CHROMA THERAPEUTICS LTD. (GB) 2015-09-15 US disclosed
US-20140163042-A1 ENZYME INHIBITORS CHROMA THERAPEUTICS LTD. (GB) 2014-06-12 US disclosed
US-20130116318-A1 Enzyme Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2013-05-09 US disclosed
EP-1879895-B1 ENZYME INHIBITORS CHROMA THERAPEUTICS LTD (GB) 2011-06-08 EP disclosed
US-7939666-B2 Enzyme inhibitors CHROMA THERAPEUTICS LTD. (GB) 2011-05-10 US disclosed
EP-2301939-A1 Enzyme inhibitors Chroma Therapeutics Limited (GB) 2011-03-30 EP disclosed
EP-2301939-A1 Enzyme inhibitors Chroma Therapeutics Limited (GB) 2011-03-30 EP disclosed
US-20090291978-A1 Enzyme Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2009-11-26 US disclosed
EP-1879895-A1 ENZYME INHIBITORS Chroma Therapeutics Limited (GB) 2008-01-23 EP disclosed
WO-2006117549-A1 ENZYME INHIBITORS CHROMA THERAPEUTICS LTD (GB) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116318-A1 Enzyme Inhibitors HDAC1, HDAC11, HDAC7 HDAC6 11/4885HDAC1 1/4885HDAC8 9/4885
US-20140163042-A1 ENZYME INHIBITORS HAT1, NR2E1, HDAC3 HDAC6 557/4885HDAC1 5/4885HDAC8 29/4885
US-20090291978-A1 Enzyme Inhibitors HAT1, NR2E1, NR2C2 HDAC6 1058/4885HDAC1 9/4885HDAC8 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.